GlassScriptPhysician profile
Rakesh R Patel
NPI 1447275201
$2,874.84
in general payments reported to CMS, 2019-2025
30 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $430 · 2021: $100 · 2022: $1,114 · 2023: $348 · 2024: $274 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $915.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $365.86 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $299.97 | 2019-2022 | |
| Lilly USA, LLC | $269.43 | 2019-2023 | Mounjaro |
| Dexcom, INC. | $180.50 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Insulet Corporation | $155.02 | 2019-2024 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.16 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $142.89 | 2020-2022 | |
| Shockwave Medical, INC | $142.82 | 2022 | |
| Boston Scientific Corporation | $138.41 | 2025 | Watchman Flx |
| Ascensia Diabetes Care US INC. | $120.33 | 2024 | |
| Zealand Pharma US, INC. | $118.63 | 2020 | |
| Novo Nordisk INC | $115.49 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $98.87 | 2019 | |
| Esperion Therapeutics, INC. | $89.05 | 2020-2021 | |
| Amphastar Pharmaceuticals, INC. | $88.99 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $68.81 | 2021-2022 | |
| Exact Sciences Corporation | $56.46 | 2024-2025 | Cologuard Collection Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.34 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.24 | 2022 | |
| Eisai INC. | $25.87 | 2024 | |
| Merck Sharp & Dohme LLC | $25.24 | 2020-2021 | |
| Genentech USA, INC. | $24.55 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $23.99 | 2022 | |
| Sanofi Pasteur INC. | $19.50 | 2023 | |
| Abiomed | $18.76 | 2023 | Impella |
| Kowa Pharmaceuticals America, INC. | $18.58 | 2019 | |
| Amgen INC. | $18.23 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.55 | 2022 | |
| Ibsa Pharma INC. | $13.33 | 2022 | |
| Alvogen INC | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.